Germany's Supreme Court Rules in Solvay's Favor on Patent Case With Neo
14.4.2021 10:00:00 EEST | Business Wire | Press release
On April 6, 2021, Germany's Federal Court of Justice (Bundesgerichtshof) ruled in Solvay's favor on a patent invalidation case filed by Neo Chemicals & Oxides (Europe) Ltd. against a patent pertaining to ceric oxide products comprising catalysts for minimizing emissions of the latest generation automotive engines, and catalysts comprising such ceric oxide products.
The appeal case at the German Federal Court of Justice (Bundesgerichtshof) reverses an invalidation decision by the Federal Patent Court (Bundespatentgericht) in January 2019 related to the German designation of the patent EP 1 435 338 B1 . This appeal decision is final and conclusive (docket number X ZR 54/19 – BGH).
The Regional Court of Mannheim (Landgericht Mannheim) had already ruled in December 2017 that Neo Chemicals & Oxides (Europe) Ltd. (“Neo”) was infringing Solvay's patent by supplying certain cerium oxide materials in Germany. In its judgment, the Mannheim court prohibited Neo and two of its directors from offering, putting on the market, using, or importing (or possessing for such reasons) the infringing products in Germany. The court had further declared that Neo was liable for damages in respect of their past sales of such infringing ceric oxide products and needed to provide an accounting of their infringing activities. Neo appealed the decision to the Higher Regional Court (Oberlandesgericht) in Karlsruhe in January 2018. The infringement appeal had been stayed by the Karlsruhe Court pending the decision of the Federal Court of Justice. As validity has now been finally and conclusively established, the German infringement appeal proceedings will be resumed. Moreover, Solvay will seek damages for the infringement of the patent in the German courts.
As previously announced, UK courts in two instances also found the patent to be valid and infringed by Neo. Another UK court case is underway to determine the amount of damages that Neo owes Solvay on the basis of this infringement.
Neo is part of the Chemicals and Oxides Segment of the Neo Performance Materials Inc. group. The production facilities of the Chemicals and Oxides Segment are in Zibo, China, and Sillamäe, Estonia.
Respect of intellectual property rights is essential for free and healthy competition. Solvay will continue to take action to enforce its rights against infringers. Solvay will help its customers to cope with any difficulties due to exposure to corresponding compliance risks by Neo.
About Solvay
Solvay is a science company whose technologies bring benefits to many aspects of daily life. With more than 23,000 employees in 64 countries, Solvay bonds people, ideas and elements to reinvent progress. The Group seeks to create sustainable shared value for all, notably through its Solvay One Planet plan crafted around three pillars: protecting the climate, preserving resources and fostering better life. The Group’s innovative solutions contribute to safer, cleaner, and more sustainable products found in homes, food and consumer goods, planes, cars, batteries, smart devices, health care applications, water and air purification systems. Founded in 1863, Solvay today ranks among the world’s top three companies for the vast majority of its activities and delivered net sales of €9 billion in 2020. Solvay is listed on Euronext Brussels (SOLB) and Paris and in the United States, where its shares (SOLVY) are traded through a Level I ADR program. Learn more at www.solvay.com.
Follow us on Twitter @SolvayGroup
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414005292/en/
Contact information
Media relations
Peter Boelaert
+32 479 309 159
peter.boelaert@solvay.com
Jeanette Stellbrink
+49 T+49 511 857 2446
jeanette.stellbrink@solvay.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 13:00:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255 million upon the full exercise of purchase warrants. The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals. The net proceeds of this financing are expected to support Agenus’ strategic prioritization of botensilimab and balstilimab (BOT+BAL) for the neoadjuvant treatment of microsatellite-stable (MSS) colon cancer, including advancement of ROBBIN1, the Company’s planned registrational Phase 3 neoadjuvant trial in microsatellite-stable (MSS) colon cancer. High-risk Stage II and Stage III MSS colon cancer affect an estimated 38,000 patients annually in the US and more than 200,000 patients worldwide,2 representing a
Zayed Sustainability Prize Closes 2027 Submissions with Strong Global Participation13.7.2026 12:48:00 EEST | Press release
The Zayed Sustainability Prize, the UAE’s pioneering award for innovative solutions to global challenges, has officially closed submissions for its 2027 awards cycle, receiving an unprecedented 10,233 entries from 177 countries across its six categories of Health, Food, Energy, Water, Climate Action and Global High Schools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713519403/en/ Zayed Sustainability Prize Closes 2027 Submissions with Strong Global Participation (Photo: AETOSWire) Now in its 18th year, the Prize continues to attract a diverse and growing pool of small and medium-sized enterprises, nonprofit organisations and high schools developing solutions that improve lives, particularly in vulnerable and underserved communities. This year’s submissions point to a growing emphasis on resilience, adaptability and systems-level impact. Across regions, applicants are addressing complex global challenges through practi
Ant Group Open-Sources SingGuard-NSFA to Establish New Security Paradigms for Autonomous AI Agents13.7.2026 12:01:00 EEST | Press release
Ant Group’s AI Security Lab today announced the open-source release of SingGuard-NSFA, a specialized security guardrail framework designed specifically for autonomous AI agents. The framework secures agentic AI systems against operational threats like prompt injection, addressing critical vulnerabilities as AI transitions from passive content generation to active, autonomous execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712722454/en/ As AI agents rapidly move from research labs to business scenarios, the security landscape has fundamentally shifted. The explosive global adoption of open-source agent frameworks like OpenClaw, celebrated for their "one-click deployment" and "full-stack autonomy", has simultaneously exposed significant operational risks, including permission escalation and prompt injection. Industry frameworks, including the OWASP (Open Web Application Security Project) Top 10 for Agentic Applica
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types13.7.2026 11:00:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, investigational monoclonal antibody for patients with von Willebrand disease (VWD). The data are being shared in an oral presentation today at the 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH 2026 Congress) in Paris. Latarcibart modulates Protein S to improve hemostasis, potentially enhancing the body’s ability to prevent or reduce the frequency of bleeding episodes. Latarcibart is in pivotal Phase 3 development for patients with VWD, the most common inherited bleeding disorder. If approved, latarcibart has the potential to be the first, once monthly subcutaneous prophylactic therapy for patients with VWD, offering an important alternative to the frequent intravenous infusions of replacement factor concentrates commonly used in the prophylactic setting today. Gi
Europe’s Demand for Tech Services Accelerates in Q2, As Spending on AI and Managed Services Rises: ISG Index™13.7.2026 11:00:00 EEST | Press release
Demand for technology services in Europe continued to accelerate in the second quarter, as the region increasingly turns to managed services to reduce costs and cloud services to meet AI objectives, according to the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows second-quarter ACV for the combined market (both managed services and cloud-based as-a-service) soared 46 percent—its largest growth in eight years—to US $13.0 billion. The latest quarter adds to a string of three straight quarters in which growth has averaged 33 percent. “Europe has become the fastest-growing region for technology services, fueled not only by an increasing demand for AI, but for managed services, which acts as a cost-savings lever to help fund AI ambitions and continued digital
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
